Allergy Therapeutics PLC Stock
€0.085
Your prediction
Allergy Therapeutics PLC Stock
Pros and Cons of Allergy Therapeutics PLC in the next few years
Pros
Cons
Performance of Allergy Therapeutics PLC vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Allergy Therapeutics PLC | 1.200% | 2.424% | 16.552% | 52.252% | 23.358% | -60.880% | - |
Beximco Pharmaceuticals Ltd. GDR | 1.420% | 0.000% | -0.465% | -4.889% | 2.885% | -50.805% | 0.000% |
SELLAS Life Sciences Group Inc | 1.290% | 0.131% | 1.190% | 42.458% | 62.593% | -37.346% | -44.665% |
Eledon Pharmaceuticals Inc. | 1.940% | 0.000% | 36.207% | 9.722% | -22.549% | 16.176% | -54.519% |
News

Why AT&T Stock Bumped Higher Today
AT&T (NYSE: T) released its latest set of quarterly results Wednesday morning. While these weren't strong enough to bring the bulls charging into the stock, they were nevertheless pleasing for

AT&T Posts 6 Percent EPS Gain in Q2
AT&T (NYSE:T), a U.S. telecommunications and connectivity provider, released its Q2 2025 earnings on July 23, 2025. The company posted adjusted earnings per share of $0.54, just above the average

Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings?
The communication services sector is having a strong year. Its 11.41% gain in 2025 makes it the third-best performer among the S&P 500’s 11 sectors, easily outpacing the index’s 7.28% gain. It’s